Full Press Release Details
Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to
Advance Clinical Strategy and Translational Oncology
Calif., June 06, 2025--NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative
treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief
Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research,
and academic medicine.
Neman joins NeOnc Technologies Holdings Inc. (NeOnc) from the Keck School of Medicine at the University of Southern California (USC),
where he serves as Associate Professor of Neurological Surgery and Physiology & Neuroscience, and Scientific Director of the USC
Brain Tumor Center. At USC, he also leads the Cancer Biology and Genomics PhD Program and serves as Director of Cancer Research Training
and Education Coordination at the USC Norris Comprehensive Cancer Center- a leading National Cancer Institute-designated cancer research
nationally recognized leader in neurooncological sciences and cancer neuroscience, Dr. Neman's research has advanced the understanding
of how brain microenvironments influence the progression of brain tumors and metastases. His pioneering studies on tumor-neuron interactions,
GABAergic signaling in cancer, and mechanisms of leptomeningeal dissemination have helped shape new therapeutic paradigms for both adult
and pediatric brain tumors.
am deeply honored to join NeOnc at this exciting time," said Dr. Neman. "NeOnc's commitment to developing innovative
therapeutics, including Blood Brain Barrier-penetrant compounds like NEO212 and NEO100, aligns perfectly with my lifelong passion to
improve outcomes for patients with brain tumors. I look forward to helping lead the translation of promising discoveries from the lab
into meaningful clinical impact."
his role as Chief Clinical Officer, Dr. Neman will lead NeOnc's clinical development strategy, including investigator-initiated
trials and precision oncology partnerships. He will also play a key role in expanding NeOnc's research collaborations with academic
institutions, regulatory agencies, and patient advocacy groups.
Neman's appointment signals a major step forward in NeOnc's mission to transform the treatment landscape for patients with
life-threatening cancers with poor outcomes," said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings,
Inc. "His academic and clinical leadership, coupled with his deep expertise in brain tumor biology, will be instrumental in accelerating
all four of our clinical trials-especially our lead asset, NEO100, which is approaching the completion of its Phase 2a trial with full
enrollment achieved ahead of schedule. As we look to add AI and quantum computing into our expanding platform in drug delivery and bio-conjugation,
Dr. Neman's appointment further strengthens our commitment to advancing precision therapies and driving toward FDA approval."
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI):
Technologies is a publicly traded, clinical-stage biopharmaceutical company developing innovative therapies for brain and central nervous
system cancers. Its lead programs-NEO100-01, NEO100-02, NEO100-03, and NEO212-utilize proprietary formulations to bypass the blood-brain
barrier and target malignancies with precision. The company's IP portfolio includes 176 patents worldwide, reflecting a broad platform
with strong commercialization potential.
more about NeOnc and its pioneering technology, visit neonc.com.
Cautions Regarding Forward-Looking Statements
statements other than statements of historical facts included in this press release are "forward-looking statements" (as
defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding
expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding
expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words
such as "projected," "expect," "possibility" and "anticipate," or similar expressions.
The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions.
Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions
made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements
are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of
the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise
revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise,
except as required by law. "NEO100" is a registered trademark of NeOnc Technologies Holdings, Inc.
Calabasas, CA, 91302
369 Lexington Avenue
Office: (646)-755-7412